Training the healthcare workforce: the global experience with telementorship for hepatitis B and hepatitis C.
Healthcare worker training
Hepatitis B
Hepatitis C
Hepatitis elimination
Project ECHO
Telehealth
Telementorship
Journal
BMC health services research
ISSN: 1472-6963
Titre abrégé: BMC Health Serv Res
Pays: England
ID NLM: 101088677
Informations de publication
Date de publication:
02 Aug 2023
02 Aug 2023
Historique:
received:
19
01
2023
accepted:
26
07
2023
medline:
4
8
2023
pubmed:
3
8
2023
entrez:
2
8
2023
Statut:
epublish
Résumé
Telementorship has emerged as an innovative strategy to decentralise medical knowledge and increase healthcare capacity across a wide range of disease processes. We report the global experience with telementorship to support healthcare workers delivering hepatitis B virus (HBV) and hepatitis C virus (HCV) care and treatment. In early 2020, we conducted a survey of HBV and HCV telementorship programmes, followed by an in-depth interview with programme leads. Programmes were eligible to participate if they were located outside of the United States (U.S.), focused on support to healthcare workers in management of HBV and/or HCV, and were affiliated with or maintained adherence to the Project ECHO model, a telementorship programme pioneered at the University of New Mexico. One programme in the U.S., focused on HCV treatment in the Native American community, was purposively sampled and invited to participate. Surveys were administered online, and all qualitative interviews were performed remotely. Descriptive statistics were calculated for survey responses, and qualitative interviews were assessed for major themes. Eleven of 18 eligible programmes completed the survey and follow up interview. Sixty-four percent of programmes were located at regional academic medical centers. The majority of programmes (64%) were led by hepatologists. Most programmes (82%) addressed both HBV and HCV, and the remainder focused on HCV only. The median number of participating clinical spoke sites per programme was 22, and most spoke site participants were primary care providers. Most ECHO sessions were held monthly (36%) or bimonthly (27%), with sessions ranging from 45 min to 2 h in length. Programme leaders identified collective learning, empowerment and collaboration to be key strengths of their telementorship programme, while insufficient funding and a lack of protected time for telementorship leaders and participants were identified as major barriers to success. The Project ECHO model for telementorship can be successfully implemented across high and low-and-middle-income countries to improve provider knowledge and experience in management of viral hepatitis. There is a tremendous opportunity to further expand upon the existing experience with telementorship to support non-specialist healthcare workers and promote elimination of viral hepatitis.
Sections du résumé
BACKGROUND
BACKGROUND
Telementorship has emerged as an innovative strategy to decentralise medical knowledge and increase healthcare capacity across a wide range of disease processes. We report the global experience with telementorship to support healthcare workers delivering hepatitis B virus (HBV) and hepatitis C virus (HCV) care and treatment.
METHODS
METHODS
In early 2020, we conducted a survey of HBV and HCV telementorship programmes, followed by an in-depth interview with programme leads. Programmes were eligible to participate if they were located outside of the United States (U.S.), focused on support to healthcare workers in management of HBV and/or HCV, and were affiliated with or maintained adherence to the Project ECHO model, a telementorship programme pioneered at the University of New Mexico. One programme in the U.S., focused on HCV treatment in the Native American community, was purposively sampled and invited to participate. Surveys were administered online, and all qualitative interviews were performed remotely. Descriptive statistics were calculated for survey responses, and qualitative interviews were assessed for major themes.
RESULTS
RESULTS
Eleven of 18 eligible programmes completed the survey and follow up interview. Sixty-four percent of programmes were located at regional academic medical centers. The majority of programmes (64%) were led by hepatologists. Most programmes (82%) addressed both HBV and HCV, and the remainder focused on HCV only. The median number of participating clinical spoke sites per programme was 22, and most spoke site participants were primary care providers. Most ECHO sessions were held monthly (36%) or bimonthly (27%), with sessions ranging from 45 min to 2 h in length. Programme leaders identified collective learning, empowerment and collaboration to be key strengths of their telementorship programme, while insufficient funding and a lack of protected time for telementorship leaders and participants were identified as major barriers to success.
CONCLUSION
CONCLUSIONS
The Project ECHO model for telementorship can be successfully implemented across high and low-and-middle-income countries to improve provider knowledge and experience in management of viral hepatitis. There is a tremendous opportunity to further expand upon the existing experience with telementorship to support non-specialist healthcare workers and promote elimination of viral hepatitis.
Identifiants
pubmed: 37533025
doi: 10.1186/s12913-023-09849-y
pii: 10.1186/s12913-023-09849-y
pmc: PMC10394928
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
824Subventions
Organisme : World Health Organization
ID : 001
Pays : International
Organisme : NIDDK NIH HHS
ID : 5T32DK007742-22
Pays : United States
Informations de copyright
© 2023. The Author(s).
Références
J Public Health Manag Pract. 2019 Sep/Oct;25 Suppl 5, Tribal Epidemiology Centers: Advancing Public Health:S97-S100
pubmed: 31348196
Hum Resour Health. 2022 Feb 4;20(1):16
pubmed: 35120542
BMJ Innov. 2017 Jul;3(3):144-151
pubmed: 29445515
J Telemed Telecare. 2018 Dec;24(10):690-696
pubmed: 30343659
Hum Resour Health. 2020 Sep 1;18(1):61
pubmed: 32873303
Acad Med. 2007 Feb;82(2):154-60
pubmed: 17264693
Open Forum Infect Dis. 2016 Jun 20;3(3):ofw123
pubmed: 27703991
Acad Med. 2016 Oct;91(10):1439-1461
pubmed: 27489018
J Biomed Inform. 2019 Jul;95:103208
pubmed: 31078660
Lancet HIV. 2021 Jan;8(1):e7
pubmed: 33387479
Aust N Z J Public Health. 2013 Oct;37(5):405-10
pubmed: 24090321
Am J Med. 2017 Apr;130(4):432-438.e3
pubmed: 27998682
Public Health Rep. 2021 Jan/Feb;136(1):39-46
pubmed: 33216679
J Biomed Inform. 2009 Apr;42(2):377-81
pubmed: 18929686
N Engl J Med. 2011 Jun 9;364(23):2199-207
pubmed: 21631316
Subst Abus. 2016;37(1):20-4
pubmed: 26848803
J Prim Care Community Health. 2021 Jan-Dec;12:21501327211019286
pubmed: 34036832
Lancet. 2017 Aug 12;390(10095):632-634
pubmed: 28816126
Open Forum Infect Dis. 2019 Jul 04;6(7):ofz128
pubmed: 31289725
Can J Gastroenterol Hepatol. 2017;2017:5324290
pubmed: 28396854
J Clin Gastroenterol. 2017 Aug;51(7):626-631
pubmed: 27811627
Dig Dis Sci. 2016 Dec;61(12):3460-3468
pubmed: 26957497
Hepatology. 2010 Sep;52(3):1124-33
pubmed: 20607688
J Contin Educ Health Prof. 2017 Fall;37(4):239-244
pubmed: 29189491
Antivir Ther. 2013;18(3 Pt B):467-73
pubmed: 23792414
J Viral Hepat. 2019 Nov;26(11):1284-1292
pubmed: 31273860
BMC Infect Dis. 2020 Jan 10;20(1):30
pubmed: 31924172
Dig Dis Sci. 2014 Jan;59(1):46-56
pubmed: 24052195
J Med Internet Res. 2020 Dec 1;22(12):e24087
pubmed: 33147166
BMC Infect Dis. 2015 Aug 19;15:353
pubmed: 26286525
Ann Emerg Med. 2021 Aug;78(2):223-228
pubmed: 34325856
Int J MS Care. 2017 Nov-Dec;19(6):283-289
pubmed: 29270085
J Acquir Immune Defic Syndr. 2022 Aug 15;90(5):538-545
pubmed: 35499527
Intern Med J. 2019 Mar;49(3):351-357
pubmed: 30091164
Pain Med. 2018 Jun 1;19(6):1140-1146
pubmed: 29036381
Clin Infect Dis. 2021 Jul 15;73(Suppl 1):S98-S105
pubmed: 33956127
Pain Med. 2017 Oct 01;18(10):1882-1889
pubmed: 29044409
Int J Equity Health. 2016 Sep 30;15(1):163
pubmed: 27716235
Epidemiol Rev. 2019 Jan 31;41(1):158-167
pubmed: 31781749
J Am Med Inform Assoc. 2020 Nov 1;27(11):1816-1818
pubmed: 32589735
J Med Virol. 2017 Apr;89(4):660-664
pubmed: 27551942
JAMA. 2016 May 10;315(18):1947-8
pubmed: 27163981
J Acquir Immune Defic Syndr. 2013 Aug 1;63(4):e125-32
pubmed: 23807157
Clin Liver Dis (Hoboken). 2019 Mar 04;13(2):43-45
pubmed: 31139354
J Acquir Immune Defic Syndr. 2014 Apr 1;65(4):414-22
pubmed: 24583614
J Gastroenterol Hepatol. 2016 Dec;31(12):1995-2003
pubmed: 27043040
J Glob Oncol. 2016 Oct 5;3(5):658-665
pubmed: 29094102
Health Policy Plan. 2018 May 1;33(4):528-538
pubmed: 29529282
J Med Educ Curric Dev. 2019 Jan 15;6:2382120518820922
pubmed: 30729170
BMJ Open Gastroenterol. 2016 Nov 10;3(1):e000119
pubmed: 27933202
Am J Manag Care. 2017 Jun;23(7 Spec No.):SP267-SP271
pubmed: 28882048
Gastroenterology. 2017 Dec;153(6):1531-1543.e2
pubmed: 29074450
Lancet Glob Health. 2021 Apr;9(4):e431-e445
pubmed: 33639097
Health Aff (Millwood). 2011 Jun;30(6):1176-84
pubmed: 21596757
Lancet Gastroenterol Hepatol. 2019 Feb;4(2):135-184
pubmed: 30647010
J Hepatol. 2019 Dec;71(6):1076-1085
pubmed: 31325468
Sex Health. 2018 Nov;15(6):601-605
pubmed: 30318034
AMA J Ethics. 2020 Oct 1;22(10):E874-881
pubmed: 33103650
Acad Med. 2017 Mar;92(3):277-278
pubmed: 28221231
Telemed J E Health. 2014 Nov;20(11):1004-8
pubmed: 25226452
J Grad Med Educ. 2018 Jun;10(3):311-315
pubmed: 29946389
PLOS Glob Public Health. 2022 Feb 23;2(2):e0000074
pubmed: 36962250
MMWR Morb Mortal Wkly Rep. 2014 May 9;63(18):393-8
pubmed: 24807237
SAGE Open Med. 2015 Oct 28;3:2050312115612805
pubmed: 26770809